RECURRENT LANGERHANS CELL HISTIOCYTOSIS
Clinical trials for RECURRENT LANGERHANS CELL HISTIOCYTOSIS explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LANGERHANS CELL HISTIOCYTOSIS trials appear
Sign up with your email to follow new studies for RECURRENT LANGERHANS CELL HISTIOCYTOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug Q702 aims to boost immune system against Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug, Q702, in about 46 adults with certain blood cancers or related diseases that have not responded to standard treatments. Q702 works by helping the immune system attack cancer cells and supporting normal blood cell production. The main goals…
Matched conditions: RECURRENT LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Promising drug targets rare childhood cancer that Won't stay away
Disease control Recruiting nowThis study tests a drug called tovorafenib in children and young adults with Langerhans cell histiocytosis (LCH), a rare disease where too many immune cells form tumors that can damage bones, skin, lungs, or the pituitary gland. The trial includes 48 people aged 6 months to under…
Matched conditions: RECURRENT LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC